文献速递心脑血管急症

阿加曲班联合静脉阿替普酶与单用静脉阿替普酶对急性缺血性卒中患者神经功能的影响:ARAIS随机临床试验

Effect of Argatroban Plus Intravenous Alteplase vs Intravenous Alteplase Alone on Neurologic Function in Patients With Acute Ischemic Stroke: The ARAIS Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01
一句话结论急性缺血性卒中患者中,阿加曲班联合阿替普酶相比单用阿替普酶未显著提高90天良好功能结局(63.8% vs 64.9%,RR 0.98,P=0.78)。

ARAIS试验为多中心、开放标签、盲法终点随机临床试验,纳入中国50家医院808例急性缺血性卒中患者,随机分为阿加曲班联合阿替普酶组(n=402)与单用阿替普酶组(n=415)。主要终点为90天改良Rankin量表评分0-1分的良好功能结局,联合组63.8% vs 单用组64.9%(风险差-1.0%,95%CI -8.1%至6.1%;RR 0.98,95%CI 0.88-1.10;P=0.78)。症状性颅内出血、实质性血肿2型及主要系统性出血发生率两组相似。结论认为联合阿加曲班未显著增加良好功能结局的可能性。

要点

  • 急性缺血性卒中发病4.5小时内,阿加曲班联合阿替普酶较单用阿替普酶未显著改善90天良好功能结局(63.8% vs 64.9%,RR 0.98,95%CI 0.88-1.10,P=0.78)。
  • 联合组症状性颅内出血2.1%(8/383)vs 单用组1.8%(7/397),实质性血肿2型2.3%(9/383)vs 2.5%(10/397),主要系统性出血0.3%(1/383)vs 0.5%(2/397)。
  • 阿加曲班用法:阿替普酶后1小时内给予静脉阿加曲班100 μg/kg推注3-5分钟,随后1.0 μg/kg/min输注48小时。
  • 阿替普酶用法:0.9 mg/kg(最大剂量90 mg),10%在1分钟内推注,余量1小时内输注。
  • 两组均接受指南推荐的治疗。

适用人群与场景

  • 发病4.5小时内的急性缺血性卒中患者,随机分组。
  • 纳入标准:急性缺血性卒中,年龄、性别不限;排除标准原文未详细列出。

诊断标准与关键阈值

  • 良好功能结局定义:90天改良Rankin量表评分0-1分(量表范围0分无症状至6分死亡)。

处置流程与药物剂量

  • 阿加曲班联合阿替普酶组:静脉阿替普酶0.9 mg/kg(最大剂量90 mg),10%在1分钟内推注,余量1小时内输注;阿替普酶后1小时内给予静脉阿加曲班100 μg/kg推注3-5分钟,随后1.0 μg/kg/min输注48小时。
  • 单用阿替普酶组:静脉阿替普酶0.9 mg/kg(最大剂量90 mg),10%在1分钟内推注,余量1小时内输注。
  • 两组均接受指南推荐的治疗。

研究设计与关键结果

  • 多中心、开放标签、盲法终点随机临床试验,中国50家医院,纳入808例急性缺血性卒中患者(随机817例),中位年龄65岁(IQR 57-71),女性238例(29.1%),中位NIHSS评分9分(IQR 7-12),760例(93.0%)完成试验。
  • 主要终点:90天良好功能结局(mRS 0-1分)联合组210/329(63.8%)vs 单用组238/367(64.9%),风险差-1.0%(95%CI -8.1%至6.1%),RR 0.98(95%CI 0.88-1.10),P=0.78。
  • 安全性:症状性颅内出血联合组2.1%(8/383)vs 单用组1.8%(7/397);实质性血肿2型2.3%(9/383)vs 2.5%(10/397);主要系统性出血0.3%(1/383)vs 0.5%(2/397)。

证据类型、等级与局限

  • 证据类型:多中心、开放标签、盲法终点随机临床试验(RCT)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于发病4.5小时内的急性缺血性卒中患者,阿加曲班联合阿替普酶相比单用阿替普酶未显著提高90天良好功能结局的可能性,不应常规联合使用。
  • 联合方案未显著增加症状性颅内出血、实质性血肿2型或主要系统性出血的发生率。

指南或共识出处

  • ARAIS随机临床试验(NCT03740958),发表于JAMA。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Previous studies suggested a benefit of argatroban plus alteplase (recombinant tissue-type plasminogen activator) in patients with acute ischemic stroke (AIS). However, robust evidence in trials with large sample sizes is lacking.

OBJECTIVE: To assess the efficacy of argatroban plus alteplase for AIS.

DESIGN, SETTING, AND PARTICIPANTS: This multicenter, open-label, blinded end point randomized clinical trial including 808 patients with AIS was conducted at 50 hospitals in China with enrollment from January 18, 2019, through October 30, 2021, and final follow-up on January 24, 2022.

INTERVENTIONS: Eligible patients were randomly assigned within 4.5 hours of symptom onset to the argatroban plus alteplase group (n = 402), which received intravenous argatroban (100 μg/kg bolus over 3-5 minutes followed by an infusion of 1.0 μg/kg per minute for 48 hours) within 1 hour after alteplase (0.9 mg/kg; maximum dose, 90 mg; 10% administered as 1-minute bolus, remaining infused over 1 hour), or alteplase alone group (n = 415), which received intravenous alteplase alone. Both groups received guideline-based treatments.

MAIN OUTCOMES AND MEASURES: The primary end point was excellent functional outcome, defined as a modified Rankin Scale score (range, 0 [no symptoms] to 6 [death]) of 0 to 1 at 90 days. All end points had blinded assessment and were analyzed on a full analysis set.

RESULTS: Among 817 eligible patients with AIS who were randomized (median [IQR] age, 65 [57-71] years; 238 [29.1%] women; median [IQR] National Institutes of Health Stroke Scale score, 9 [7-12]), 760 (93.0%) completed the trial. At 90 days, 210 of 329 participants (63.8%) in the argatroban plus alteplase group vs 238 of 367 (64.9%) in the alteplase alone group had an excellent functional outcome (risk difference, -1.0% [95% CI, -8.1% to 6.1%]; risk ratio, 0.98 [95% CI, 0.88-1.10]; P = .78). The percentages of participants with symptomatic intracranial hemorrhage, parenchymal hematoma type 2, and major systemic bleeding were 2.1% (8/383), 2.3% (9/383), and 0.3% (1/383), respectively, in the argatroban plus alteplase group and 1.8% (7/397), 2.5% (10/397), and 0.5% (2/397), respectively, in the alteplase alone group.

CONCLUSIONS AND RELEVANCE: Among patients with acute ischemic stroke, treatment with argatroban plus intravenous alteplase compared with alteplase alone did not result in a significantly greater likelihood of excellent functional outcome at 90 days.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03740958.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Chen HS, Cui Y, Zhou ZH, et al. Effect of Argatroban Plus Intravenous Alteplase vs Intravenous Alteplase Alone on Neurologic Function in Patients With Acute Ischemic Stroke: The ARAIS Randomized Clinical Trial. JAMA. 2023. PMID: 36757755. doi:10.1001/jama.2023.0550

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。